Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

Neuroscience

Volumn 170, Issue 4, 2010, Pages 1239-1248

  Wang, X H ^a   Li, L ^a   Holscher C ^b   Pan, Y F ^a   Chen, X R ^a   Qi, J S ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimer's disease; Cognition; Diabetes; Neurodegeneration; Neuroprotection; Synaptic plasticity

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; GLUCAGON LIKE PEPTIDE 1 [7-36][8 VALINE]; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 (7 36), VAL(8); GLUCAGON-LIKE PEPTIDE 1 (7-36), VAL(8)-; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFICACY; EXCITATORY POSTSYNAPTIC POTENTIAL; EXPERIMENTAL TEST; HIPPOCAMPUS; IN VIVO STUDY; LEARNING DISORDER; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SWIMMING; SYNAPTIC TRANSMISSION; ANIMAL; DRUG EFFECT; HIPPOCAMPAL CA1 REGION; MAZE TEST; MEMORY; PHYSIOLOGY; VISION; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; CA1 REGION, HIPPOCAMPAL; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUCAGON-LIKE PEPTIDE 1; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; SWIMMING; SYNAPTIC TRANSMISSION; VISION, OCULAR;

EID: 77957126457     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.08.028     Document Type: Article

References (44)

1. Abbas T., Faivre E., Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009, 205:265-271.
2. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
3. Cullen W.K., Suh Y.H., Anwyl R., Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 1997, 8:3213-3217.
4. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
5. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987, 84:3434-3438.
6. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
7. Ferreira S.T., Vieira M.N., De Felice F.G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 2007, 59:332-345.
8. Frey U., Huang Y.Y., Kandel E.R. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 1993, 260:1661-1664.
9. Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol 2006, 31:133-147.
10. Gault V.A., Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008, 587:112-117.
11. Gengler S., McClean P., McCurtin R., Gault V., Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2010, 10.1016/j.neurobiolaging.2010.02.014.
12. Gilman C.P., Perry T., Furukawa K., Grieg N.H., Egan J.M., Mattson M.P. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 2003, 87:1137-1144.
13. Green B.D., Lavery K.S., Irwin N., O'Harte F.P., Harriott P., Greer B., Bailey C.J., Flatt P.R. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 2006, 318:914-921.
14. Hamilton A., Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009, 20:1161-1166.
15. Holscher C. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev Neurosci 2005, 16:181-212.
16. Holscher C. Val(8)GLP-1, a protease-resistant incretin analogue, prevents the impairment of hippocampal synaptic plasticity in an APP/PS-1 mouse model of Alzheimer's disease. Alzheimers Dement 2009, 5:325.
17. Hölscher C., Gengler S., Gault V., Harriott P., Mallot H. Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 2007, 561:85-90.
18. Holscher C., Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?. Neurobiol Aging 2010, 31:1495-1502.
19. Holst J.J. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994, 107:1848-1855.
20. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004, 490:115-125.
21. Huang H.J., Liang K.C., Chen C.P., Chen C.M., Hsieh-Li H.M. Intrahippocampal administration of A beta(1-40) impairs spatial learning and memory in hyperglycemic mice. Neurobiol Learn Mem 2007, 87:483-494.
22. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr Rev 1999, 20:876-913.
23. Li L., Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007, 56:384-402.
24. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010, 19:1205-1219.
25. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
26. MacDonald P.E., El-Kholy W., Riedel M.J., Salapatek A.M., Light P.E., Wheeler M.B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002, 51(Suppl 3):S434-S442.
27. Nitta A., Fukuta T., Hasegawa T., Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 1997, 73:51-57.
28. Orskov C., Wettergren A., Holst J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993, 42:658-661.
29. Perry T., Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2005, 2:377-385.
30. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002, 300:958-966.
31. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003, 72:603-612.
32. Qi J.S., Qiao J.T. Amyloid beta-protein fragment 31-35 forms ion channels in membrane patches excised from rat hippocampal neurons. Neuroscience 2001, 105:845-852.
33. Qi J.S., Qiao J.T. Suppression of large conductance Ca2+-activated K+ channels by amyloid beta-protein fragment 31-35 in membrane patches excised from hippocampal neurons. Sheng Li Xue Bao 2001, 53:198-204.
34. Qi J.S., Ye L., Qiao J.T. Amyloid beta-protein fragment 31-35 suppresses delayed rectifying potassium channels in membrane patches excised from hippocampal neurons in rats. Synapse 2004, 51:165-172.
35. Qiu W.Q., Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006, 27:190-198.
36. Stewart R., Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999, 16:93-112.
37. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 2002, 99:13217-13221.
38. Wang Q.W., Rowan M.J., Anwyl R. Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. Neurobiol Aging 2009, 30:1608-1613.
39. Yan X.Z., Qiao J.T., Dou Y., Qiao Z.D. Beta-amyloid peptide fragment 31-35 induces apoptosis in cultured cortical neurons. Neuroscience 1999, 92:177-184.
40. Ye C., Walsh D.M., Selkoe D.J., Hartley D.M. Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci Lett 2004, 366:320-325.
41. Ye L., Qiao J.T. Suppressive action produced by beta-amyloid peptide fragment 31-35 on long-term potentiation in rat hippocampus is N-methyl-D-aspartate receptor-independent: it's offset by (-)huperzine A. Neurosci Lett 1999, 275:187-190.
42. Zetterberg H., Blennow K., Hanse E. Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol 2009, 45:23-29.
43. Zhang J.F., Qi J.S., Qiao J.T. Protein kinase C mediates amyloid beta-protein fragment 31-35-induced suppression of hippocampal late-phase long-term potentiation in vivo. Neurobiol Learn Mem 2009, 91:226-234.
44. Zhang J.M., Wu M.N., Qi J.S., Qiao J.T. Amyloid beta-protein fragment 31-35 suppresses long-term potentiation in hippocampal CA1 region of rats in vivo. Synapse 2006, 60:307-313.